CA3246779A1 - SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND THEIR PREPARATION METHOD - Google Patents
SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND THEIR PREPARATION METHODInfo
- Publication number
- CA3246779A1 CA3246779A1 CA3246779A CA3246779A CA3246779A1 CA 3246779 A1 CA3246779 A1 CA 3246779A1 CA 3246779 A CA3246779 A CA 3246779A CA 3246779 A CA3246779 A CA 3246779A CA 3246779 A1 CA3246779 A1 CA 3246779A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- salt
- free base
- degrees
- hci salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22151820.2 | 2022-01-17 | ||
| EP22151820 | 2022-01-17 | ||
| EP22170332.5 | 2022-04-27 | ||
| EP22170332 | 2022-04-27 | ||
| PCT/EP2023/050883 WO2023135303A1 (en) | 2022-01-17 | 2023-01-16 | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3246779A1 true CA3246779A1 (en) | 2023-07-20 |
Family
ID=84982261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3246779A Pending CA3246779A1 (en) | 2022-01-17 | 2023-01-16 | SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND THEIR PREPARATION METHOD |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250115565A1 (https=) |
| EP (1) | EP4466255A1 (https=) |
| JP (1) | JP2025502300A (https=) |
| KR (1) | KR20240134979A (https=) |
| AU (1) | AU2023206628A1 (https=) |
| CA (1) | CA3246779A1 (https=) |
| CL (1) | CL2024002124A1 (https=) |
| IL (1) | IL314188A (https=) |
| MX (1) | MX2024008821A (https=) |
| PY (1) | PY2302301A (https=) |
| TW (1) | TW202337444A (https=) |
| UY (1) | UY40111A (https=) |
| WO (1) | WO2023135303A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319024A (en) * | 2022-08-29 | 2025-04-01 | Assembly Biosciences Inc | Pharmaceutical preparations for the herpes virus |
| IL325911A (en) | 2023-07-17 | 2026-03-01 | Innovative Molecules Gmbh | Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds |
| WO2026078039A1 (en) | 2024-10-09 | 2026-04-16 | Innovative Molecules Gmbh | Oral administration forms of antiviral helicase-primase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10131128A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| GEP20207128B (en) | 2016-04-06 | 2020-07-10 | Molecules Gm Innovative | Aminothiazole derivatives useful as antiviral agents |
| MX2020003369A (es) | 2017-10-05 | 2020-07-29 | Innovative Molecules Gmbh | Enantiomeros de tiazoles sustituidos como compuestos antivirales. |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| KR20230131177A (ko) | 2020-10-29 | 2023-09-12 | 이노베이티브 몰리큘스 게엠베하 | 항바이러스 화합물로서 중수소화된 아미노티아졸 화합물 |
-
2023
- 2023-01-16 EP EP23700877.6A patent/EP4466255A1/en active Pending
- 2023-01-16 KR KR1020247027250A patent/KR20240134979A/ko active Pending
- 2023-01-16 JP JP2024542125A patent/JP2025502300A/ja active Pending
- 2023-01-16 TW TW112101829A patent/TW202337444A/zh unknown
- 2023-01-16 AU AU2023206628A patent/AU2023206628A1/en active Pending
- 2023-01-16 MX MX2024008821A patent/MX2024008821A/es unknown
- 2023-01-16 UY UY0001040111A patent/UY40111A/es unknown
- 2023-01-16 CA CA3246779A patent/CA3246779A1/en active Pending
- 2023-01-16 IL IL314188A patent/IL314188A/en unknown
- 2023-01-16 WO PCT/EP2023/050883 patent/WO2023135303A1/en not_active Ceased
- 2023-01-16 PY PY202302302301A patent/PY2302301A/es unknown
- 2023-01-16 US US18/729,411 patent/US20250115565A1/en active Pending
-
2024
- 2024-07-15 CL CL2024002124A patent/CL2024002124A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240134979A (ko) | 2024-09-10 |
| MX2024008821A (es) | 2024-07-29 |
| WO2023135303A1 (en) | 2023-07-20 |
| US20250115565A1 (en) | 2025-04-10 |
| PY2302301A (es) | 2023-10-31 |
| TW202337444A (zh) | 2023-10-01 |
| UY40111A (es) | 2023-08-15 |
| IL314188A (en) | 2024-09-01 |
| AU2023206628A1 (en) | 2024-08-01 |
| EP4466255A1 (en) | 2024-11-27 |
| JP2025502300A (ja) | 2025-01-24 |
| CL2024002124A1 (es) | 2024-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250115565A1 (en) | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof | |
| TWI729530B (zh) | 吡咯并〔２，３－ｄ〕嘧啶甲苯磺酸鹽類、其晶形以及其製造方法及中間體 | |
| JP7407171B2 (ja) | グリコシダーゼ阻害剤として有用なピペラジン誘導体のコハク酸付加塩及びフマル酸付加塩 | |
| US11834443B2 (en) | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol | |
| BR112019020840A2 (pt) | sais farmacêuticos, formas físicas e composições de inibidores da pirrolopirimidina quinase e métodos de produção dos mesmos | |
| US20150183779A1 (en) | Solid state form of vemurafenib choline salt | |
| JP2020525475A (ja) | Ｎ−［１−（５−シアノ−ピリジン−２−イルメチル）−１ｈ−ピラゾール−３−イル］−２−［４−（１−トリフルオロメチル−シクロプロピル）−フェニル］−アセタミドの結晶形 | |
| JP2023552274A (ja) | 抗ウイルス化合物としての重水素化アミノチアゾール化合物 | |
| CN114075169B (zh) | 奥希替尼药用共晶体及其制备方法 | |
| CN121532378A (zh) | 抗病毒解旋酶-引发酶抑制剂化合物的微粉化结晶盐酸盐 | |
| CN114728982A (zh) | 固体形式的s1p-受体调节剂 | |
| CN118556045A (zh) | 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法 | |
| EA052003B1 (ru) | Твердые кристаллические формы ингибиторов геликазы-примазы и способ их получения | |
| EP3481801B1 (en) | Indoline derivatives and method for using and producing the same | |
| HK40110051A (zh) | 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法 | |
| TW202330496A (zh) | 用於製備大麻素受體調節劑之結晶形式及方法 | |
| US20250304635A1 (en) | Birinapant polymorph h | |
| RU2787767C2 (ru) | Кристалл производного бензоксазола | |
| TW201908320A (zh) | 一種ｂｔｋ激酶抑制劑的結晶形式及製備方法 | |
| AU2023270440A1 (en) | Crystal forms of triazine dione derivative and preparation method therefor | |
| JP2025528116A (ja) | ５，６－ジヒドロチエノ［３，４－ｈ］キナゾリン類化合物の塩型、結晶型およびその調製方法 | |
| JP2023524622A (ja) | ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体 | |
| HK40054619B (zh) | 吡咯并[2，3-d]嘧啶甲苯磺酸盐、其结晶形式以及有关的制备方法和中间体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240704 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241121 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241121 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241125 |